Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.thyrocare.com | |
Market Cap | 3,223.76 Cr. | |
Enterprise Value(EV) | 3,222.91 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 12.27 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 49.63 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 63.07 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 91.83 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 6.63 | Calculated using Price: 608.80 |
Dividend Yield | 2.96 | Period Ending 2023-03 |
No. of Shares Subscribed | 5.30 Cr. | 52,952,676 Shares |
FaceValue | 10 | |
About Thyrocare Technologies Ltd. | ||
Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively. |
1 Day |
|
-1.85% |
1 Week |
|
+9.29% |
1 Month |
|
+11.54% |
3 Month |
|
+7.68% |
6 Month |
|
+28.06% |
1 Year |
|
-5.74% |
2 Year |
|
-43.89% |
5 Year |
|
+11.36% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 15.98 | 16.22 | 11.20 | 22.16 | 19.41 | 22.13 | 28.75 | 37.18 | 12.23 | |
Return on Capital Employed (%) | 24.57 | 25.66 | 21.05 | 33.93 | 31.36 | 35.14 | 38.51 | 48.42 | 17.61 | |
Return on Assets (%) | 13.41 | 14.09 | 10.20 | 20.59 | 17.93 | 18.73 | 22.43 | 25.38 | 7.65 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 276 | 366 | 408 | 443 | 435 | 367 | 427 | 527 | 534 | 486 | |
Non Curr. Liab. | 9 | 10 | 9 | 10 | 14 | 21 | 18 | 106 | 149 | 23 | |
Curr. Liab. | 7 | 31 | 18 | 20 | 21 | 82 | 95 | 215 | 151 | 69 | |
Minority Int. | 36 | 1 | 1 | ||||||||
Equity & Liab. | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 848 | 835 | 579 | |
Non Curr. Assets | 218 | 273 | 285 | 332 | 334 | 317 | 300 | 427 | 488 | 370 | |
Curr. Assets | 111 | 134 | 150 | 142 | 136 | 152 | 240 | 421 | 347 | 209 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 848 | 835 | 579 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 547 | |
Other Income | 8 | 7 | 12 | 23 | 10 | 7 | 12 | 29 | 8 | 9 | |
Total Income | 191 | 248 | 317 | 380 | 413 | 441 | 507 | 618 | 535 | 556 | |
Total Expenditure | -110 | -147 | -189 | -212 | -249 | -261 | -323 | -353 | -404 | -422 | |
PBIDT | 81 | 101 | 128 | 168 | 164 | 180 | 184 | 265 | 131 | 134 | |
Interest | 0 | -1 | 0 | 0 | -1 | -2 | -1 | -3 | -5 | -3 | |
Depreciation | -13 | -18 | -18 | -20 | -26 | -32 | -30 | -34 | -39 | -41 | |
Taxation | -24 | -30 | -39 | -52 | -53 | -52 | -39 | -52 | -24 | -25 | |
Exceptional Items | -27 | -2 | -7 | ||||||||
PAT | 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 63 | |
Minority Interest | 1 | 0 | |||||||||
Share Associate | 1 | 1 | 1 | ||||||||
Other Related Items | 0 | -1 | 0 | 2 | |||||||
Consolidated Net Profit | 45 | 52 | 43 | 93 | 85 | 89 | 112 | 176 | 66 | 65 | |
Adjusted EPS | 9 | 10 | 8 | 17 | 16 | 17 | 21 | 33 | 12 | 12 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | |
Cash Fr. Inv. | -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | |
Cash Fr. Finan. | -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | |
Net Change | -6 | 5 | 0 | 0 | -5 | 4 | 4 | 0 | 4 | |
Cash & Cash Eqvt | 5 | 10 | 10 | 10 | 5 | 9 | 13 | 14 | 18 |
Mon, 04 Dec 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Participate in corporate road show arranged by InCred Equities |
Fri, 01 Dec 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS This is to inform you that the Nomination and Remuneration Committee of the Company through a resolution by circulation passed on December 01 2023 has approved the allotment of 22 633 equity shares of face value of Rs.10/- each pursuant to exercise of options under ESOP 2020. |
Tue, 21 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of copy of newspaper advertisement notice to equity shareholders regarding unclaimed equity shares due for transfer to IEPF |
Fri, 08 Dec 2023 |
|
|
|
|
|